2017 American Transplant Congress
Kidney Transplant Allocation with CMV Matching Reduces CMV Infection and Related Costs.
Cytomegalovirus (CMV) infection is a major cause of morbidity, mortality, and shortened graft survival in kidney transplant recipients. Efforts to prevent CMV infection have traditionally…2017 American Transplant Congress
Reproducibility of the Cobas CMV Test (cobas CMV) and Clinical Concordance with the Cobas Ampliprep / Cobas TaqMan CMV Test (CAP/CTM CMV).
cobas CMV is a new, automated, high-throughput assay for use on the cobas 6800/8800 systems that quantifies CMV DNA in EDTA-plasma. It can be run…2017 American Transplant Congress
Kidney Allocation Using CMV Matching Optimizes Low and High Risk Profiles for Prevention of CMV Infection in Kidney Transplant Recipients.
Cytomegalovirus (CMV) confers a major impact on morbidity, mortality, and graft survival in kidney transplant recipients. Efforts to prevent CMV disease and infection have traditionally…2017 American Transplant Congress
Cytomegalovirus Renal Infection: Rare Manifestation of a Common Post-Transplant Viral Infection — A Case Series.
Cytomegalovirus is the most common viral infection in organ transplant recipients. CMV disease commonly manifests as meningoencephalitis, pneumonitis, hepatitis, and colitis. Kidney involvement of CMV…2017 American Transplant Congress
Contribution of New Generation Sequencing to CMV Resistance Analysis in Renal Transplant Recipients (on Behalf of the CMV Resist Group).
Results from the French Cohorts 2006-2010 and OrphaVic (NCTNCT02067169) indicates that fifty percent of graft failures in renal recipients infected by HCMV after treatment with…2017 American Transplant Congress
Cost Effectiveness of Post-Prophylaxis Screening Strategies for Cytomegalovirus Viremia in CMV D+R- Kidney Transplant Recipients.
Purpose: To assess cost-effectiveness(CE) of screening for CMV after 6 months of valganciclovir prophylaxis in CMV high-risk (D+R-) kidney transplant recipients.Methods: A Markov model was…2017 American Transplant Congress
Immediate vs Delayed Initiation of CMV Prophylaxis…Safe and Cost Beneficial?
University of Utah Health Care, Salt Lake City, UT
Background: Recommendations differ on when to initiate valganciclovir (VGCV) for CMV prophylaxis (ppx) after tx. Current labeling states within 10 days of tx. We evaluated…2017 American Transplant Congress
Prospective Randomized Trial for Predicting CMV Infection According to Baseline CMV-Specific T-Cell Immunity in Kidney Transplant Patients.
Background: Despite the use of either anti-viral prophylaxis (PF) or preemptive (PE) therapy given based on donor/recipient IgG-serostatus, Cytomegalovirus (CMV) reactivation persists after kidney transplantation…2017 American Transplant Congress
Utility of “High-Dose” Ganciclovir in High Viral Load CMV Infection in Transplant Recipients.
Background: High-dose ganciclovir (GCV) is often used for treatment of high viral load CMV, but few data exist on virologic outcomes and risk of neutropenia.…2017 American Transplant Congress
Rates of CMV Infection in Kidney Transplant Recipients Who Received Subtherapeutic Valganciclovir Prophylaxis.
Purpose: The aim of this study was to compare the rate of cytomegalovirus (CMV) infection after kidney transplantation in high and intermediate risk patients who…
- « Previous Page
- 1
- …
- 20
- 21
- 22
- 23
- 24
- …
- 33
- Next Page »